During the past decade, Franciscan Health Indianapolis conducted 116 clinical trials. In the 10-year time frame, 116 clinical trials started and 86 clinical trials were completed, i.e. on average, 74.1% percent of trials that started reached the finish line to date. In the past 5 years, 41 clinical trials started and 53 clinical trials were completed. i.e. 129.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Franciscan Health Indianapolis" #1 sponsor was "National Cancer Institute (NCI)" with 56 trials, followed by "SWOG Cancer Research Network" with 26 trials sponsored, "Alliance for Clinical Trials in Oncology" with 15 trials sponsored, "Eli Lilly and Company" with 6 trials sponsored and "NRG Oncology" with 6 trials sponsored. Other sponsors include 89 different institutions and companies that sponsored additional 65 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Franciscan Health Indianapolis" #1 collaborator was "National Cancer Institute (NCI)" with 63 trials as a collaborator, "NRG Oncology" with 14 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "Cancer and Leukemia Group B" with 4 trials as a collaborator and "NCIC Clinical Trials Group" with 4 trials as a collaborator. Other collaborators include 62 different institutions and companies that were collaborators in the rest 62 trials.

According to Clinical.Site data, the most researched conditions in "Franciscan Health Indianapolis" are "Breast Cancer" (12 trials), "Coronary Artery Disease" (7 trials), "Recurrent Squamous Cell Lung Carcinoma" (7 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (6 trials) and "Multiple Myeloma" (5 trials). Many other conditions were trialed in "Franciscan Health Indianapolis" in a lesser frequency.

Most popular intervention types in "Franciscan Health Indianapolis" are "Drug" (146 trials), "Other" (86 trials), "Biological" (57 trials), "Procedure" (35 trials) and "Device" (31 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (42 trials), "Quality-of-Life Assessment" (30 trials), "Paclitaxel" (19 trials), "Placebo" (17 trials) and "Carboplatin" (16 trials). Other intervention names were less common.

The vast majority of trials in "Franciscan Health Indianapolis" are 172 trials for "All" genders, 30 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Franciscan Health Indianapolis". undefined are not yet recruiting, 31 are recruiting, 77 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 73 completed trials in Franciscan Health Indianapolis, 1 suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in Franciscan Health Indianapolis, 7 "Phase 1" clinical trials were conducted, 64 "Phase 2" clinical trials and 106 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 20 trials that are defined as “Not Applicable".